David Scheinberg

David Scheinberg, MD, PhD, is a prominent academic at Memorial Sloan Kettering Cancer Center (MSKCC), serving as Chair of the Center for Experimental Therapeutics and Deputy Director of the Sloan Kettering Institute for Therapeutic Discovery. He holds a dual degree from Johns Hopkins University School of Medicine (MD and PhD, 1983) and a BA from Cornell University (1977). His research focuses on developing targeted immunotherapies, including antibodies, nanodevices, and vaccines, with an emphasis on translating these innovations into clinical trials.

Key areas of investigation include molecular nanogenerators for cancer therapy, T-cell engager antibodies targeting oncogenic proteins (e.g., WT1), and cellular micropharmacies. His lab’s work spans biotechnology, protein engineering, and nanotechnology, aiming to combat cancer through innovative approaches. Collaborations with institutions like Princeton University and industry partnerships (e.g., Actinium, Arvinas) highlight his translational research impact.

Dr. Scheinberg’s academic contributions include pioneering targeted alpha-particle therapies and vaccine development for clinical trials. He actively mentors graduate students and researchers, though he is no longer accepting new students. His leadership roles underscore his commitment to advancing therapeutic discovery in oncology and immunology.